5 Stocks Under $10 Set to Soar
Ziopharm Oncology
Another under-$10 name that's trading very close to triggering a near-term breakout trade is Ziopharm Oncology (ZIOP), a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. This stock is off to a decent start in 2012, with shares up around 16% on the year.
>>22 Biopharma Stocks With Breakout Potential in 2012
If you take a look at the chart for Ziopharm Oncology, you'll notice that this stock recently dropped sharply from around $4.75 to a low of $3.36 a share with heavy volume. Following that plunge, shares of ZIOP have rebounded sharply to its current price of around $5.10 a share. That rebound is quickly pushing ZIOP within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in ZIOP if it can manage to trigger a break out above some near-term overhead resistance levels at $5.31 to $5.75 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 639,378 shares. If that breakout triggers soon, then ZIOP will setup to re-test or possibly take out its next major overhead resistance levels at $6.02 to $6.33 a share. Any high-volume move above $6.33 will put $7 to $7.85 into focus for ZIOP. Traders can look to buy ZIOP off any weakness, and simply use a stop that sits just below some near-term support at $5 a share. One could also buy ZIOP once it clears its 50-day at $5.20 with high volume. Look to add to either position once ZIOP takes out $5.31 to $5.75 a share, and then once it clears $6.02 to $6.33 a share with high volume.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV